Drug updated on 4/30/2024
Dosage Form | Injection (intravenous; 2 g/vial [1 g meropenem (equivalent to 1.14 g meropenem trihydrate) and 1 g vaborbactam]) |
Drug Class | Antibacterials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.
Summary
- Meropenem and vaborbactam (Vabomere) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonectitis caused by designated susceptible bacteria.
- Two systematic reviews/meta-analyses were reviewed to gather information about Vabomere's efficacy in treating cUTIs.
- The first review found that novel antibiotics, such as meropenem/vaborbactam, demonstrated a higher clinical cure rate (CCR) and microbiological eradication rate at test of cure compared to conventional antibiotics used for cUTIs.
- However, there was no significant difference observed in CCR or risk of treatment-emergent adverse events between the intervention group treated with novel antibiotics like Vabomere and control groups at end of treatment according to this study.
- The second meta-analysis revealed that meropenem/vaborbactam had higher clinical and microbiological success rates than other carbapenems when treating cUTI but also showed a higher risk of adverse events.
- This analysis suggested meropenem/vaborbactam as a first-choice treatment especially for complicated urinary tract infections caused by carbapenem-resistant uropathogens due its high effectiveness despite the increased risk associated with it.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vabomere (meropenem and vaborbactam) Prescribing Information. | 2023 | Melinta Therapeutics, LLC., Lincolnshire, IL |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: a systematic review and meta-analysis of randomized controlled trials. | 2023 | International Journal of Antimicrobial Agents |
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection. | 2020 | Medicine Open |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. | 2023 | Infectious Disease Society of America |
Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). | 2021 | Clinical Infectious Diseases |